SAN DIEGO, Aug. 30, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that Martin Auster, M.D. has departed from his role as Chief Financial Officer, effective August 30, 2024. Roy Gonzales, CPA, MBA, the Company’s SVP of Finance, has assumed the roles of interim Principal Financial Officer and interim Principal Accounting Officer for SEC reporting purposes. The company has initiated a search for a CFO.
“Marty has been a valued member of our executive team over these past three years,” said Raju Mohan, Ph.D., Chief Executive Officer. “I want to thank Marty for his contributions to Ventyx’s success, including leading the Company through its initial public offering, managing financial and governance matters, and supporting investor relations. We wish him well in his future endeavors.”
“It has been a privilege to work as part of Ventyx’s leadership team and I am proud of our accomplishments,” said Dr. Auster. “I wish the Company great success in the future.”
About Ventyx Biosciences
Ventyx is a clinical-stage biopharmaceutical company focused on advancing novel oral therapies for patients living with inflammatory diseases. We believe our ability to efficiently discover and develop differentiated drug candidates will allow us to address important unmet medical need with novel oral therapies that can shift inflammation markets from injectable to oral drugs. Our current pipeline includes internally discovered clinical programs targeting NLRP3, S1P1R and TYK2, positioning us to become a leader in the development of oral therapies for peripheral and neuroinflammatory diseases. Ventyx is headquartered in San Diego, California. For more information about Ventyx, please visit www.ventyxbio.com.
Investor Relations Contact
Patti Bank
Managing Director
ICR Westwicke
(415) 513-1284
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$1.97 |
| Daily Change: | -0.05 -2.48 |
| Daily Volume: | 1,318,777 |
| Market Cap: | US$139.220M |
November 07, 2024 October 15, 2024 September 23, 2024 September 06, 2024 August 08, 2024 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
